Serogroup B Meningococcus Outbreaks, Prevalence, and the Case for Standard Vaccination

James Grogan, Karen Roos

Research output: Contribution to journalReview article

7 Citations (Scopus)

Abstract

Purpose of Review: This review explores the history of serogroup B meningitis outbreaks in American universities and the rise of the monovalent serogroup B meningococcus vaccines (MenB). Recent Findings: Serogroup B meningitis represents 30% of American meningococcal infections and had no commercially available vaccine in the USA until 2013 when the FDA made an expanded allowance for importation of the MenB-4C vaccine for outbreaks at two American universities. Summary: Infections of Neisseria meningitidis, notably meningococcal meningitis represent a continued, lethal threat to the pediatric and adolescent populations and those with primary or acquired complement component deficiencies, largely mitigated by the quadrivalent meningococcal conjugated vaccine against serogroups A, C, W, and Y (MenACWY).

Original languageEnglish (US)
Article number30
JournalCurrent Infectious Disease Reports
Volume19
Issue number9
DOIs
StatePublished - Sep 1 2017

Fingerprint

Serogroup B Neisseria meningitidis
Disease Outbreaks
Vaccination
Vaccines
Meningitis
Meningococcal Vaccines
Meningococcal Infections
Meningococcal Meningitis
Neisseria meningitidis
History
Pediatrics
Infection
Population
Serogroup

All Science Journal Classification (ASJC) codes

  • Infectious Diseases

Cite this

@article{e74e12bb8bff4d00b1c41f95edb33d4b,
title = "Serogroup B Meningococcus Outbreaks, Prevalence, and the Case for Standard Vaccination",
abstract = "Purpose of Review: This review explores the history of serogroup B meningitis outbreaks in American universities and the rise of the monovalent serogroup B meningococcus vaccines (MenB). Recent Findings: Serogroup B meningitis represents 30{\%} of American meningococcal infections and had no commercially available vaccine in the USA until 2013 when the FDA made an expanded allowance for importation of the MenB-4C vaccine for outbreaks at two American universities. Summary: Infections of Neisseria meningitidis, notably meningococcal meningitis represent a continued, lethal threat to the pediatric and adolescent populations and those with primary or acquired complement component deficiencies, largely mitigated by the quadrivalent meningococcal conjugated vaccine against serogroups A, C, W, and Y (MenACWY).",
author = "James Grogan and Karen Roos",
year = "2017",
month = "9",
day = "1",
doi = "10.1007/s11908-017-0587-4",
language = "English (US)",
volume = "19",
journal = "Current Infectious Disease Reports",
issn = "1523-3847",
publisher = "Current Science, Inc.",
number = "9",

}

Serogroup B Meningococcus Outbreaks, Prevalence, and the Case for Standard Vaccination. / Grogan, James; Roos, Karen.

In: Current Infectious Disease Reports, Vol. 19, No. 9, 30, 01.09.2017.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Serogroup B Meningococcus Outbreaks, Prevalence, and the Case for Standard Vaccination

AU - Grogan, James

AU - Roos, Karen

PY - 2017/9/1

Y1 - 2017/9/1

N2 - Purpose of Review: This review explores the history of serogroup B meningitis outbreaks in American universities and the rise of the monovalent serogroup B meningococcus vaccines (MenB). Recent Findings: Serogroup B meningitis represents 30% of American meningococcal infections and had no commercially available vaccine in the USA until 2013 when the FDA made an expanded allowance for importation of the MenB-4C vaccine for outbreaks at two American universities. Summary: Infections of Neisseria meningitidis, notably meningococcal meningitis represent a continued, lethal threat to the pediatric and adolescent populations and those with primary or acquired complement component deficiencies, largely mitigated by the quadrivalent meningococcal conjugated vaccine against serogroups A, C, W, and Y (MenACWY).

AB - Purpose of Review: This review explores the history of serogroup B meningitis outbreaks in American universities and the rise of the monovalent serogroup B meningococcus vaccines (MenB). Recent Findings: Serogroup B meningitis represents 30% of American meningococcal infections and had no commercially available vaccine in the USA until 2013 when the FDA made an expanded allowance for importation of the MenB-4C vaccine for outbreaks at two American universities. Summary: Infections of Neisseria meningitidis, notably meningococcal meningitis represent a continued, lethal threat to the pediatric and adolescent populations and those with primary or acquired complement component deficiencies, largely mitigated by the quadrivalent meningococcal conjugated vaccine against serogroups A, C, W, and Y (MenACWY).

UR - http://www.scopus.com/inward/record.url?scp=85026850600&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85026850600&partnerID=8YFLogxK

U2 - 10.1007/s11908-017-0587-4

DO - 10.1007/s11908-017-0587-4

M3 - Review article

AN - SCOPUS:85026850600

VL - 19

JO - Current Infectious Disease Reports

JF - Current Infectious Disease Reports

SN - 1523-3847

IS - 9

M1 - 30

ER -